Long-term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway, Ireland Purpose:...
Guardado en:
Autores principales: | Abdalla A, Byrne N, Conway R, Walsh T, Mannion G, Hanly M, O'Sullivan M, Curran AM, Carey JJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0836fca57a1c4dfb9924d297e9233ad3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Review of biologics, biosimilars, and intended copies in rheumatology, and current practice in Iraq
por: Al Ani NA, et al.
Publicado: (2018) -
Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald T, et al.
Publicado: (2021) -
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
por: Mysler E, et al.
Publicado: (2021) -
Management of ankylosing spondylitis with infliximab
por: Éric Toussirot, et al.
Publicado: (2009) -
Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study
por: Franz Thiele, et al.
Publicado: (2021)